

Effect of brimonidine, measured with the Nerve Fibre Analyser, in patients with acute ischaemic optic neuropathy

Submission date 20/12/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 20/12/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 05/11/2008	Condition category Eye Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr H G Lemij

Contact details
Oogziekenhuis Rotterdam
Schiedamsevest 180
Rotterdam
Netherlands
3011 BH
+31 (0)10 401 7777
Lemij@oogziekenhuis.nl

Additional identifiers

Protocol serial number
OZR-2000-07; NTR139

Study information

Scientific Title

Acronym

AION

Study objectives

Administration of brimonidine eye drops in patients with acute ischaemic optic neuropathy (AION) reduces loss of vision.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Received from local medical ethics committee

Study design

Randomised, double-blind, placebo controlled, parallel group, two-arm trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Acute ischaemic optic neuropathy

Interventions

Topical treatment with brimonidine (0.5%) eye drops.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Brimonidine

Primary outcome(s)

Thickness of peripapillary nerve fiber layer.

Key secondary outcome(s)

No secondary outcome measures

Completion date

01/08/2002

Eligibility**Key inclusion criteria**

Arteric or non-arteric AION

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

1. Onset of symptoms greater than 5 days ago at presentation
2. Inability to undergo GDx or HFA measurement

Date of first enrolment

01/02/2001

Date of final enrolment

01/08/2002

Locations**Countries of recruitment**

Netherlands

Study participating centre

Oogziekenhuis Rotterdam

Rotterdam

Netherlands

3011 BH

Sponsor information**Organisation**

Rotterdam Eye Hospital (Oogziekenhuis Rotterdam) (The Netherlands)

ROR

<https://ror.org/02hjc7j46>

Funder(s)

Funder type

Research organisation

Funder Name

Foundation of Scientific Research at the Eye Hospital (Stichting Wetenschappelijk Onderzoek het Oogziekenhuis) (The Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration